Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.62 |
| ▸ | LPL | P06858 | 12/20 | 0.62 |
| ▸ | P4HB | P07237 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CA9 | Q16790 | 3/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA3 | P07451 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.45 |
| ▸ | F11 | P03951 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL235805 | 0.94 | LPL (0.53) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL4940298 | 0.88 | LIPG (0.49) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL23219387 | 0.85 | LPL (0.46) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL3789949 | 0.85 | P4HB (0.46) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL15583750 | 0.85 | LPL (0.46) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL2707320 | 0.84 | LIPG (0.83) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL24608995 | 0.84 | LIPG (0.83) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL3803514 | 0.82 | LIPG (0.43) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL20639937 | 0.81 | ALDH1A1 (0.55) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL3778232 | 0.80 | LIPG (0.51) | LIPGLPLP4HBCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023097189-A1 | AMPK ACTIVATORS | KALLYOPE, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023097189-A1 | AMPK ACTIVATORS | KALLYOPE, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023097187-A1 | AMPK ACTIVATORS | KALLYOPE, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023097187-A1 | AMPK ACTIVATORS | KALLYOPE, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| EP-4172162-A1 | AMPK ACTIVATORS | Kallyope, Inc. (US) | 2023-05-03 | — | — | EP | disclosed |
| US-20220340599-A1 | AMPK ACTIVATORS | KALLYOPE, INC. | 2022-10-27 | — | — | US | disclosed |
| US-20220340599-A1 | AMPK ACTIVATORS | KALLYOPE, INC. | 2022-10-27 | — | — | US | disclosed |
| US-11407768-B2 | AMPK activators | KALLYOPE, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| US-20220002317-A1 | AMPK ACTIVATORS | KALLYOPE, INC. | 2022-01-06 | — | — | US | disclosed |
| US-20220002317-A1 | AMPK ACTIVATORS | KALLYOPE, INC. | 2022-01-06 | — | — | US | disclosed |
| WO-2021263039-A1 | AMPK ACTIVATORS | KALLYOPE, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| WO-2021263039-A1 | AMPK ACTIVATORS | KALLYOPE, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| WO-2010100475-A1 | HYDROXAMIC ACID DERIVATIVES AS GRAM-NEGATIVE ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010100475-A1 | HYDROXAMIC ACID DERIVATIVES AS GRAM-NEGATIVE ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002317-A1 | AMPK ACTIVATORS | PRKAG1, PRKAG2, PRKAA1 | LIPG 596/4885LPL 436/4885P4HB 4704/4885 |
| US-11407768-B2 | AMPK activators | PRKAG1, PRKAG2, PRKAA1 | LIPG 596/4885LPL 436/4885P4HB 4704/4885 |
| US-20220340599-A1 | AMPK ACTIVATORS | PRKAG1, PRKAG2, PRKAA1 | LIPG 596/4885LPL 436/4885P4HB 4704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.